Open AccessContrast-enhanced [18F] fluorodeoxyglucose-positron emission tomography-computed tomography as an initial imaging modality in patients presenting with metastatic malignancy of undefined primary origin
Author(s) -
Anjali Jain,
Madhur Kumar Srivastava,
Alok Pawaskar,
Shelley Simon,
Indirani Elangovan,
Hasmukh Jain,
Somnath Pandey,
Shilpa Kalal,
Jaykanth Amalachandran
Publication year - 2015
Publication title -
indian journal of nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 13
eISSN - 0972-3919
pISSN - 0974-0244
DOI - 10.4103/0972-3919.158529
Subject(s) - medicine , malignancy , positron emission tomography , radiology , biopsy , primary tumor , fluorodeoxyglucose , nuclear medicine , metastasis , pathology , cancer
To evaluate the advantages of contrast enhanced F-18-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-contrast enhanced CT [CECT]) when used as an initial imaging modality in patients presenting with metastatic malignancy of undefined primary origin (MUO).